[Docetaxel (taxotere) for therapy of breast carcinoma. Highest effectiveness with moderate side effects].
RESULTS
Docetaxel is a taxan which has proven high efficacy in the treatment of breast cancer. The results are consistent throughout all phases of clinical evaluation. High response rates have been observed especially for women after failure of anthracyclins or with liver metastases. Response rates are superior to doxorubicin, while the extent of the side effects is comparable.


CONCLUSIONS
Due to the different toxicity profile a combination of docetaxel and anthracyclins is feasible and has already been demonstrated in early clinical trials. The role of the combinatory treatments in first line or adjuvant setting is currently under investigation.
von Minckwitz
G
G
Klinik für Gynäkologie und Geburtshilfe, Johann Wolfgang Goethe-Universität Frankfurt. minckwitz@em.uni-frankfurt.de
Costa
S D
SD
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary*; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015996:Survival Rate; D043823:Taxoids
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel